← Back to Search

Omega-3 Fatty Acid

Ethyl Eicosapentaenoic Acid for Bipolar Disorder

Phase 4
Waitlist Available
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six weeks
Awards & highlights

Study Summary

This study is evaluating whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation.

Eligible Conditions
  • Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and six weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Montgomery Asberg Rating Scale

Side effects data

From 2018 Phase 3 trial • 8179 Patients • NCT01492361
9%
Diarrhoea
8%
Hypertension
8%
Nasopharyngitis
8%
Upper respiratory tract infection
8%
Back pain
8%
Arthralgia
7%
Bronchitis
6%
Cataract
6%
Influenza
6%
Dizziness
6%
Cough
6%
Dyspnoea
6%
Fatigue
6%
Urinary tract infection
6%
Oedema peripheral
6%
Chest pain
6%
Pain in extremity
5%
Constipation
4%
Anaemia
3%
Pneumonia
2%
Osteoarthritis
1%
Syncope
1%
Atrial fibrillation
1%
Gastrointestinal haemorrhage
1%
Non-cardiac chest pain
1%
Cellulitis
1%
Prostate cancer
1%
Angina pectoris
1%
Angina unstable
1%
Chronic obstructive pulmonary disease
1%
Sepsis
1%
Acute kidney injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
AMR101
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ethyl eicosapentaenoic acidExperimental Treatment1 Intervention
Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day

Find a Location

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
475 Previous Clinical Trials
153,907 Total Patients Enrolled
18 Trials studying Bipolar Disorder
2,327 Patients Enrolled for Bipolar Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid
Martin Lan 2021. "A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04811404.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top